3 Global Generics, Branded Generics and Contract Formulations Stocks With a Strong Future Roadmap: Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab

Generic and branded pharma stocks follow the companies that make everyday medicines for patients in India and abroad. Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab show three models: a global generics major, a branded generics company with a strong domestic franchise and a contract manufacturer with its own formulations.

This list covers three generic and branded pharma stocks with complete current figures: Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic and Branded Pharma Stocks?

Generic and branded pharma stocks are listed companies that make and sell off-patent medicines under their own names or as contract manufacturers. Their earnings depend on volumes, approvals, product mix and plant utilisation.

Generic and Branded Pharma Stocks at a Glance

On valuation, Aurobindo Pharma and Emcure Pharmaceuticals trade at a P/E below the industry P/E, while Innova Captab trades above it, which reflects the growth the market already expects. Readers comparing generic and branded pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Generic and Branded Pharma Stocks Have a Strong Roadmap in India?

Generic and branded pharma stocks have a strong roadmap in India because healthcare systems at home and abroad rely on affordable medicines and Indian companies have scale and compliance records.

• Affordable medicines. Generics widen access to treatment in India and overseas.
• Contract manufacturing. Drug brands outsource production to reliable partners.
• Product expansion. Injectables and biosimilars add higher-value lines.

Why Aurobindo Pharma Features Among These Generic and Branded Pharma Stocks

Among the generic and branded pharma stocks on this list, Aurobindo Pharma is a Hyderabad-based pharmaceutical company that makes generic formulations, active ingredients and injectables, with the United States and Europe as its largest markets.

The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0.

Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore.

Roadmap: The company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.

What to watch: Monitor new product launches and progress on its biosimilars and injectables pipeline.

Why Emcure Pharmaceuticals Features Among These Generic and Branded Pharma Stocks

Among the generic medicine shares on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.

Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.

In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.

Roadmap: It is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.

What to watch: Look at the growth of the India branded business and the pace of new launches abroad.

Why Innova Captab Features Among These Generic and Branded Pharma Stocks

Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.

In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.

Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.

Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.

Aurobindo Pharma vs Emcure Pharmaceuticals vs Innova Captab on Key Financials

The table below sets the three generic and branded pharma stocks side by side on revenue, profit and margin, using reported figures.

Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Aurobindo Pharma has the largest FY26 revenue at Rs 34,145 crore, and Innova Captab shows the fastest revenue growth with a 19.5% compound annual rate. A useful habit with generic and branded pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Generic and Branded Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these generic and branded pharma stocks, the main points are: Long-term generic medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Price erosion. Generic prices in regulated markets can change with competition.
• Regulatory audits. Plant inspections can influence supply.
• Input costs. Raw material prices can influence margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter generic and branded pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Generic and Branded Pharma Stocks

Generic and branded pharma stocks reward investors who study approvals, capacity and product mix. Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab each give a different route to growing earnings. Based on the 20 October 2026 close, Aurobindo Pharma trades at Rs 1,621.4, Emcure Pharmaceuticals at Rs 1,766.6 and Innova Captab at Rs 1,001.7. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these generic and branded pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track generic and branded pharma stocks, set price alerts and get research-backed stock ideas.

What are generic and branded pharma stocks?

Ans. Generic and branded pharma stocks are listed companies that make and sell off-patent medicines under their own names or as contract manufacturers. Their earnings depend on volumes, approvals, product mix and plant utilisation. This list looks at three of them, Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which generic and branded pharma stocks are covered in this list?

Ans. This list covers Aurobindo Pharma, Emcure Pharmaceuticals and Innova Captab. Based on the 20 October 2026 close, Aurobindo Pharma traded at Rs 1,621.4, Emcure Pharmaceuticals at Rs 1,766.6 and Innova Captab at Rs 1,001.7. Their return on equity ranges from 9.2% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.5% to 19.5%.

Why do generic and branded pharma stocks have a strong future roadmap in India?

Ans. Generic and branded pharma stocks have a strong roadmap in India because healthcare systems at home and abroad rely on affordable medicines and Indian companies have scale and compliance records. The main drivers are as follows. Affordable medicines. Generics widen access to treatment in India and overseas. Contract manufacturing. Drug brands outsource production to reliable partners. Product expansion. Injectables and biosimilars add higher-value lines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Aurobindo Pharma performed financially?

Ans. Revenue rose from Rs 23,776 crore in FY22 to Rs 34,145 crore in FY26, a compound annual growth rate of 9.5%. Net profit grew from Rs 2,647 crore in FY22 to Rs 3,503 crore in FY26, which works out to a compound annual growth rate of 7.3%. In the June 2026 quarter, revenue grew 18.1% year on year to Rs 9,415 crore, while net profit rose 25.2% to Rs 1,032 crore. The company has a return on equity of 9.2%, a debt to equity ratio of 0.21 and a market capitalisation of Rs 92,924 crore. The stock trades at a P/E of 25.0, below the industry P/E of 36.0. Looking ahead, the company is widening its range into injectables, biosimilars and complex generics while keeping a large base in oral solid dosages. Its integrated manufacturing from ingredients to finished products supports supply to regulated markets.

How has Emcure Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.

How has Innova Captab performed financially?

Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.

What risks should investors check before buying generic and branded pharma stocks?

Ans. Investors should check a few risks before buying generic and branded pharma stocks. Price erosion. Generic prices in regulated markets can change with competition. Regulatory audits. Plant inspections can influence supply. Input costs. Raw material prices can influence margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of generic and branded pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.